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Abstract
Loss of retinoblastoma (Rb) tumor suppressor function is associated with human malignancies. Molecular and genetic
mechanisms responsible for tumorigenic Rb downregulation are not fully defined. Through a forward genetic screen and
positional cloning, we identified and characterized a zebrafish ubiquitin specific peptidase 39 (usp39) mutation, the yeast and
human homolog of which encodes a component of RNA splicing machinery. Zebrafish usp39 mutants exhibit microcephaly
and adenohypophyseal cell lineage expansion without apparent changes in major hypothalamic hormonal and regulatory
signals. Gene expression profiling of usp39 mutants revealed decreased rb1 and increased e2f4, rbl2 (p130), and cdkn1a (p21)
expression. Rb1 mRNA overexpression, or antisense morpholino knockdown of e2f4, partially reversed embryonic pituitary
expansion in usp39 mutants. Analysis of pre-mRNA splicing status of critical cell cycle regulators showed misspliced Rb1 pre-
mRNA resulting in a premature stop codon. These studies unravel a novel mechanism for rb1 regulation by a neuronal
mRNA splicing factor, usp39. Zebrafish usp39 regulates embryonic pituitary homeostasis by targeting rb1 and e2f4
expression, respectively, contributing to increased adenohypophyseal sensitivity to these altered cell cycle regulators. These
results provide a mechanism for dysregulated rb1 and e2f4 pathways that may result in pituitary tumorigenesis.
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Introduction
The hypothalamic-pituitary axis regulates stress responses,
growth, reproduction and energy homeostasis. Neuropeptides
released from the hypothalamus via the hypophyseal portal plexus
control synthesis and secretion of anterior pituitary hormones [1].
Different pituitary cell types secrete hormones that regulate post-
natal growth (growth hormone, GH), lactation (prolactin, PRL),
metabolism (thyroid stimulating hormone, TSH), stress (adreno-
corticotrophic hormone, ACTH), pigmentation (melanocyte-
stimulating hormone, aMSH), sexual development and reproduc-
tion (luteinizing hormone, LHb, and follicle stimulating hormone,
FSHb) [2]. Corticotropes and melanotropes produce proopiome-
lanocortin (POMC), which is proteolytically cleaved to give rise to
ACTH in corticotropes and aMSH in melanotropes.
Central and peripheral signals including hypothalamic stimu-
latory hormones, growth factors and estrogen cause pituitary
hyperplasia, genetic instability, subsequent monoclonal growth
expansion and tumor formation [3]. Pituitary tumors are almost
invariably benign, however if untreated, they are associated with
increased morbidity and mortality due to tumor mass effect and/
or hormonal disruptions leading to serious complications such as
acromegaly and Cushing’s disease [4,5]. How developmental or
acquired signals elicit plastic change in pituitary cell growth
resulting in hyperplasia or benign adenomas is not fully
understood [6].
The pituitary gland is highly sensitive to cell cycle regulators
including cyclins, cyclin dependent kinases (CDKs), CDK
inhibitors (CKIs) and retinoblastoma protein (pRB), all of which
are frequently dysregulated in pituitary tumors. pRB, a nuclear
pocket protein, binds the E2F transcription factors and regulates
the balance between cell quiescence and proliferation [7]. E2Fs
control expression of genes crucial for cell cycle re-entry, DNA
replication and mitosis. Dephosphorylated pRB binds to E2Fs and
inhibits transcription of E2F target genes either by sequestration
and inhibition of E2F cell cycle ‘‘activators’’ (E2F1–E2F3), or by
formation of pocket protein complexes with ‘‘inhibitors’’ (E2F4–
E2F8), which bind to E2F-responsive promoters and repress their
transcription [7]. Accordingly, transcriptional repression of pRB
activity prevents G1/S progression and promotes cell quiescence.
In mice, Rb heterozygous mutations lead to early onset and
increased incidence of endocrine neoplasma including pituitary,
thyroid and adrenal tumors [8,9]. The 100% penetrance of
pituitary tumors in Rb
+/2 mice [8] is partially reversed in Rb
+/2;
E2f4
2/2 double mutants, implicating the Rb/E2f4 pathway in
pituitary tumorigenesis and also suggesting an E2F4 oncogenic
activity [9]. E2F4 is also known as a key regulator associated with
p130 in G0/G1 to promote quiescent G0 and terminal
differentiation [10,11]. E2f4 null mice often die shortly after birth
with defects of terminal differentiation resulting from an inability
to establish cell cycle quiescence [12]. In response to cell cycle re-
entry, E2F4 switches from p130 [10,13] to pRB [10,14] and p107
[10,14,15], which inhibit E2F4 transactivation. Additionally, E2F4
overexpression has been shown to promotes cell proliferation and
transformation [14,15], which prevents growth arrest mediated by
p130 [13].
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fish [2]. Novel insights into developmental mechanisms have been
obtained by in vivo analysis of transgenic zebrafish expressing GFP
and RFP driven by regulatory elements of zebrafish pomc [16] and
prl [17], respectively. Through a forward genetic screen for novel
zebrafish genes regulating adenohypophyseal pomc gene expres-
sion, we identified and characterized a mutant that harbors a
nonsense mutation in usp39, leading to expansion of all
adenohypophyseal cell lineages.
Usp39 encodes a conserved protein termed Sad1p in Saccharo-
myces cerevisiae and a 65 kDa (65K) SR-related protein in humans
[18,19]. Both yeast Sad1p and the 65K SR-related protein in
humans are involved in assembly of the spliceosome, the RNA
splicing machinery [18,19]. RNA splicing is crucial for eukaryotic
gene expression and defective splicing can be detrimental since it
leads to an altered genetic message [20]. The spliceosome consists
of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4,
U5 and U6 as well as a large number of non-snRNP proteins [20].
The yeast Sad1p is involved in splicing in vivo and in vitro and in the
assembly of U4 snRNP to U6 snRNP [18], while human 65K SR-
related protein is essential for recruitment of the tri-snRNP to the
pre-spliceosome and is known as a tri-snRNP-specific protein
[19,21]. Additionally, Usp39 is also classified as a deubiquitinating
enzyme but lacks protease activity due to absence of key active-site
residues of cysteine and histidine [18,19,22].
In the present study, we aimed to define novel pathways
regulating pituitary development through study of an usp39
mutation. Using microarray gene expression profiling followed
by quantitative real time-polymerase chain reaction (RT-PCR)
validation we observed a significant reduction of rb1 expression
and increased e2f4, rbl2 (p130) and cdkn1a (p21) expression in
mutants. Zebrafish usp39 is predominantly expressed in the brain
and represents a novel neuronal splicing factor. We show that
zebrafish usp39 mutation leads to an rb1 splicing defect responsible
for pituitary expansion. In addition, knockdown of e2f4 partially
rescued pomc lineage expansion in usp39 mutants. Our finding that
usp39 regulates expansion of all embryonic pituitary cell lineages
through the rb1/e2f4 pathway may shed light on mechanisms
underlying adult pituitary tumor formation.
Results
The hp689 locus encodes usp39
To isolate genes required for adenohypophysis and hypotha-
lamic development a standard forward genetics method was
carried out using a three-generation (F3) screen after mutagenesis
with ENU, which mostly induces single nucleotide exchanges at
random positions of the genome [23–25]. The genetic screen was
performed using pomc expression as a specific marker. pomc is
expressed in subepithelial pituitary cells, dorsal to the oral
ectoderm roof and ventral to the ventral diencephalon. A subset
of pomc-expressing cells is also located outside the adenohypoph-
ysis, corresponding to b-endorphin-synthesizing cells of the
hypothalamic arcuate nucleus [2]. In zebrafish, spatial distribution
of the six different hormone secreting pituitary cell types is
subdivided into three regions along the antero-posterior adeno-
hypophyseal axis of the rostral pars distalis, proximal pars distalis
and pars intermedia [2]. pomc is expressed in corticotropes of the
rostral pars distalis, in melanotropes of the pars intermedia and in
the hypothalamus (Figure 1A).
We isolated an ENU-induced mutant, hp689, which was
characterized by reduced hypothalamic but increased pituitary
pomc expression at 48-hours post fertilization (hpf) (Figure 1B). In
addition, hp689 mutants displayed microcephaly and smaller eyes
starting at 33 hpf (data not shown). Using segregation linkage
analysis, the hp689 locus was mapped to zebrafish linkage group 5
with a critical interval of 0.03 centimorgan (cM) on marker ndrg3
(Figure 1C, see Materials and Methods). This region contained 7
annotated genes and sequencing of usp39 from mutant embryos
revealed a point mutation that converted a TAT codon into a
TAA in exon 11, resulting in a premature termination codon
rather than a tyrosine amino acid (Figure 1D). PROSITE database
search of the Usp39 protein revealed two domains consisting of a
zinc finger (ZF_UBP) and a Ubiquitin carboxyl-terminal hydro-
lases family 2 (UCH_2_3) region [26]. As a result of the UCH_2_3
domain, Usp39 is classified as a deubiquitinating enzyme.
However, it lacks protease activity due to the absence of key
active site cysteine and histidine residues [18,19,22]. The single
allele of hp689 carries a nonsense mutation within the UCH_2_3
region, resulting in a truncated Usp39 protein lacking amino acids
after position 412 (Figure 1D).
To confirm that hp689 represents the usp39 mutation, a usp39
antisense morpholino (MO) oligonucleotide targeting the usp39
start codon and consequentially blocking translation was injected
into wild-type (wt) embryos [27]. MO injected embryos showed
increased pomc expression, similar to the hp689 phenotype
(Figure 1F compared to Figure 1B). Furthermore, injection of
mRNA encoding wild-type usp39 rescued the mutant phenotype
(Table 1), indicating that pituitary pomc upregulation in usp39
mutants results from the nonsense mutation in zebrafish usp39.
usp39 is predominantly expressed in the zebrafish
embryonic brain
RNA whole-mount in situ hybridization was performed to
determine the spatiotemporal expression pattern of usp39 during
zebrafish development. Generally weak usp39 expression was
detected in early cleavage embryos (data not shown) but tissue
specific expression peaked by 36 hpf and decreased by 42 hpf
(Figure 2A–2C). Expression was detected predominantly within
the brain, including the pituitary region and eyes. At 21.5 hpf,
there was also expression in the intermediate cell mass, the site of
embryonic zebrafish hematopoiesis (Figure 2A, inset). However,
mutants showed persistently lower usp39 expression that was
completely lost by 42 hpf (Figure 2D). In addition, loss of usp39
expression by 42 hpf corresponds to the time at which the usp39
mutant embryos fully develop a phenotype of microcephaly,
smaller eyes and a pituitary abnormality, indicating the critical
time point when usp39 is required for normal development.
Author Summary
Previous studies have shown that Rb
+/2 mice develop
pituitary adenomas; however, RB1 mutations have not
been found in human pituitary tumors. In the present
study, we uncovered a novel genetic pathway that may
lead to Rb downregulation through RNA splicing mediated
by usp39, a gene involved in assembly of the spliceosome.
Our forward genetic study in zebrafish suggests that loss
of usp39 results in aberrant rb1 mRNA splicing, which likely
causes elevated expression of its target e2f4, a key
regulator known to have oncogenic activity when
overexpressed. We established that e2f4 upregulation is a
main factor responsible for the adenohypophyseal cell
lineage hyperplasia observed in the zebrafish usp39
mutant. It should be of interest to investigate if mutations
or downregulation of USP39 would contribute to pituitary
tumorigenesis in humans.
Splicing Factor usp39 Role in Pituitary Cells
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The zebrafish adenohypophysis consists of six different
hormone-secreting cell types distributed along the anterior-
posterior axis: lactotropes and corticotropes are located anteriorly
in the rostral pars distalis, thyrotropes, gonadotropes and
somatotropes are found medially in the proximal pars distalis
whereas melanotropes are situated posteriorly in the pars
intermedia (Figure 3). To determine if additional pituitary lineages
are affected by the usp39 mutation, we performed double color
RNA in situ hybridization analysis with combinatory pituitary
Figure 1. hp689 is a novel zebrafish gene encoding usp39. A, B, E, F: Whole-mount in situ hybridization with pomc probe at 48 hpf, ventral view
with anterior to left. (A) Wild-type (wt) embryo, pomc is expressed in the rostral pars distalis (black arrow), the pars intermedia (the red arrow), and in
the b-endorphin-synthesizing neurons of the hypothalamus (asterisk). The medial domain which lacks pomc expression corresponds to the proximal
pars distalis. (B) The hp689 mutant exhibits increased pomc expression in the adenohypophysis, and lower expression in the hypothalamus compared
to wt. (C) Genomic map of linkage group 5 (LG5) and position of the hp689 mutation (in red) and mapping markers based on meiotic segregation
linkage analysis. hp689 mapped close to markers z34450 and ndrg3 that were located 2.4 cM and 0.3 cM, respectively (see Materials and Methods). (D)
Schematic representation of the Usp39 protein, which include a zinc finger and ubiquitin carboxyl-terminal hydrolases family 2 domains with the
hp689 mutation from a tyrosine to a stop codon indicated in red. (E) Non-injected wt control embryos. (F) wt embryos injected with usp39 MO. Note
increased pomc expression and disorganization of the adenohypophysis similar to the increased expression of pomc in usp39 mutant embryos in (B).
doi:10.1371/journal.pgen.1001271.g001
Table 1. usp39 mRNA overexpression rescues the mutant
usp39 phenotype.
Injection Total # Mutant # %
Control 161 38 24
usp39 mRNA 128 3 2
doi:10.1371/journal.pgen.1001271.t001
Splicing Factor usp39 Role in Pituitary Cells
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encodes the glycoprotein a-subunit heterodimerizing with TSHb,
LHb, or FSHb subunit [2,16]. This analysis revealed expansion
of all the analyzed cell lineages without apparent cell fate
transformation in the usp39 mutant pituitary at 48 hpf
(Figure 3A–3P). Cell expansion was most marked in corticotropes
and lactotropes, indicating that usp39 is important for regulating
embryonic pituitary cell populations (Figure 3B, 3D, 3F, 3H, 3J,
and 3L).
Pituitary lineage expansion in usp39 mutants is
independent of hypothalamic releasing hormone and
dopamine signals
We examined expression of hypothalamic regulators to
investigate whether pituitary lineage expansion in usp39 mutants
is due to altered hypothalamic neuroendocrine input to the
adenohypophysis. One of the primary hypothalamic inhibitory
mechanisms controlling pituitary homeostasis is dopamine (DA)
released from tuberoinfundibular neurons (TIDA). Pituitary
lactotrophs are almost exclusively regulated by tonic inhibition
of dopamine, which inhibits lactotroph proliferation, PRL gene
expression and secretion by activating D2 dopamine receptor
subtype (Drd2) [28]. We therefore processed 48 hpf whole-mount
embryos for immunocytochemistry using an antibody against
tyrosine-hydroxylase, the rate-limiting enzyme of dopamine
synthesis in TIDA neurons, and detected no significant change
of hypothalamic dopaminergic neurons in usp39 mutants com-
pared with wt siblings (Figure 4D and 4H). Corticotropin releasing
hormone (CRH) as well as gonadotropin-releasing hormone
(GnRH) stimulates cell growth, hormone synthesis and secretion
of pituitary corticotropes and gonadotropes, respectively [29,30].
However, usp39 mutants exhibit no altered crh or gnrh expression
(Figure 4E–4G). Therefore, pituitary lineage expansion of usp39
mutants occurs independently of major hypothalamic neuroendo-
crine signals.
Pituitary transcription factors are upregulated during late
stage of development in usp39 mutants
We next studied expression of transcription factors important
for adenohypophyseal development. Lim3/Lhx3 is one of the
earliest pituitary specifying transcription factors and is required for
progenitor proliferation and survival [2]. Pitx3, a Pitx/Rieg
Figure 2. Whole-mount in situ hybridization analysis of the zebrafish usp39 expression pattern. Embryonic ages are shown in the lower
right corner, lateral view. A–C: Expression of usp39 in wt is found in the brain and eye region. (A) Inset shows additional usp39 expression in the
intermediate cell mass, site of embryonic zebrafish hematopoiesis. (B) usp39 expression is highest at 36 hpf. (C) usp39 expression declines by 42 hpf.
(D) The expression pattern of usp39 in usp39 mutants is lower in all stages; expression at 42 hpf is depicted.
doi:10.1371/journal.pgen.1001271.g002
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Whole-mount double in situ hybridization with probes indicated on the side. usp39 mutant embryos exhibit higher expression of all pituitary
hormone markers compared to wild-type (wt) embryos. Spatial distribution of prl, tsh, pomc and cga are normal in the usp39 mutant. (A, B, E, F, I, J, M,
and N) ventral view and (C, D, G, H, K, L, O, and P) lateral view, with anterior to the left. Columns 1 (A, E, I, and M) and 3 (C, G, K and O) show wt
siblings; columns 2 (B, F, J, and N) and 4 (D, H, L, and P) show usp39 mutant embryos. A–D: gh (purple) and prl (red) transcripts. (C) The spatial
distribution of gh is normally found in the proximal pars distalis (white arrow) and prl is found in the rostral pars distalis (black arrow). (D) Note the
spatial distribution of gh in the usp39 mutant; gh is abnormally expressed in the rostral pars distalis (black arrow). E–H: tsh (purple) and pomc (red)
transcripts. I–L: prl (purple) and pomc (red) transcripts. M–P: Whole-mount in situ hybridization with cga transcript.
doi:10.1371/journal.pgen.1001271.g003
Figure 4. The hypothalamic releasing hormone and dopamine signals are unaffected in usp39 mutants. A–C and E–G: Whole-mount in
situ hybridization with hypothalamic probes at 48 hpf, ventral view. (A–C) wild-type (wt) embryos. (E–G) usp39 mutant embryos. Expression of
hypothalamic markers crh, gnrh2, and gnrh3 did not change. D and H: Immunocytochemistry with tyrosine hydroxylase (TH) antibody at 48 hpf,
ventral view. (H) Expression of TH in usp39 mutant embryos did not change.
doi:10.1371/journal.pgen.1001271.g004
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required for Lim3 expression [2]. Pit1 is a Pou domain
homeoprotein and a lineage-determining factor for somatotropes,
lactotropes and thyrotropes [2]. The Drosophila eye absent
homolog, eya1, is required for specification of gonadotropes,
corticotropes, and melanotropes [2]. Zebrafish mutation of ascl1a,
a homolog of the Drosophila MASH1 [31], resulted in failed
endocrine differentiation of all adenohypohyseal cell types [2].
Expression of these zebrafish pituitary regulators coincides within
the pituitary placode of the anterior neural ridge (ANR) at 20-
somite stage (18 hpf) and persists in the adenohypophyseal anlage
throughout 48 hpf (for eya1), or even later (for pit1, lim3, pitx3, and
ascl1a). At 36 hpf, usp39 mutants exhibited no increased expression
of lim3, however pit1, lim3, pitx3, eya1 and ascl1a showed a
significant expression difference at a later state (48 hpf) compared
with wt (Figure S1, Figure 5). These results suggest that the usp39
mutation did not affect initial embryonic pituitary progenitor
specification but induced their expansion after 36 hpf.
usp39 mutants exhibit altered expression of cell cycle
regulators including rb1 and e2f4
To distinguish whether the altered pituitary signals detected by
whole-mount in situ hybridization is due to pituitary hyperplasia
or higher expression of pituitary hormone levels we crossed usp39
+/2 fish to POMC-GFP transgenic fish [16]. After identifying
mutant usp39 in the POMC-GFP background, we sectioned usp39
and wt whole embryos and performed immunocytochemistry with
anti-GFP followed by cell number quantification. Our results
demonstrated that there was an increase in the number of POMC-
GFP-positive cells in usp39 mutants compare to wt (Figure S2A–
S2F). In addition, counting the nuclei stained with DAPI indicated
an increase in the total number of pituitary cells in the usp39
mutant compare to wt embryos (Figure S2G). We carried out a
BrdU incorporation study and demonstrated that the increase in
pituitary cell number seen in usp39 mutants was due to an increase
in proliferation (Figure S2H and S2I). It is well established that cell
cycle dysregulation is associated with pituitary pathology in animal
models and human disease [32]. However, little is known about
mechanisms underlying the sensitivity of differentiated pituitary
cell lineages to cell cycle regulators. We therefore performed a
microarray analysis and focused on cell cycle regulators, 11 of
which were confirmed for altered expression in usp39 mutants by
quantitative RT-PCR. In summary, expression levels of 3 genes
were increased including e2f4, rbl2 (p130) and cdkn1a (p21) and
expression of the other 8 cell cycle genes including rb1 were
downregulated (Table 2; Figure S3).
We further examined e2f4 expression by RNA whole-mount in
situ hybridization, which confirmed its upregulation in the
adenohypophysis of usp39 mutants compared to wt embryos
(Figure 6A and 6B). To investigate whether e2f4 upregulation is
responsible for adenohypophysis lineage expansion, we injected
embryos with antisense MO oligonucleotide to knockdown e2f4
function. The overall usp39 mutant phenotype maintained after
e2f4 MO injections, which resulted in partial reversal of pomc
expansion in e2f4-MO-injected usp39 embryos at 48 hpf compared
to control embryos (Figure 6C–6E, mutant N=20, ,60% showed
rescue). The phenotypic rescue of usp39 embryos by e2f4-MO is
pituitary specific since pomc hypothalamic expression was not
altered. In addition, we analyzed prl expression and a partial
rescue was also observed in e2f4-MO-injected usp39 embryos
(Figure S4). These results indicate that loss of usp39 results in
increased e2f4 expression, which at least partially contributes to the
observed pomc lineage expansion in zebrafish adenohypophysis.
rb1 splicing defect contributes to the usp39 mutant
phenotype
Since usp39 is known to be an essential component of the RNA
splicing machinery, the more than 70% decrease of rb1 expression
in usp39 mutants may be attributed to defects in RNA splicing. We
therefore examined rb1 splicing status by PCR amplification using
primers corresponding to each end of 19 out of 27 exons of the rb1
gene. Primers designed for exon 3 and exon 4 resulted in a PCR
product of 250 base pairs (bp) in wt and mutant embryos,
representing a correctly spliced mRNA fragment. However,
mutant embryos exhibited an additional larger PCR product of
343 bp (Figure 6F). Further DNA sequence analysis revealed that
the 343 bp PCR product derived from usp39 mutants contain the
Figure 5. Loss of usp39 leads to pituitary expansion as
indicated by increased expression of pituitary transcription
factors. A–F and G–J: Single and double in situ hybridization with
probes indicated on the side, at 48 hpf, ventral view, anterior to the left.
(A, C, E, G, and I) wild-type (wt) embryos. (B, D, F, H, and J) usp39 mutant
embryos have increased pituitary expression of pit1, lim3, pitx3, eya1,
and ascl1a.
doi:10.1371/journal.pgen.1001271.g005
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splicing defect would lead to a premature stop codon in the intron
between exon 3 and exon 4 of rb1 (data not show), which would
lead to nonsense-mediated mRNA decay. We then performed an
rb1 mRNA overexpression experiment in usp39 mutants and
observed partial rescue of the adenohypophysis phenotype
(Figure 6I, mutant N=34, ,50% showed rescue), validating the
importance of usp39-mediated rb1 mRNA splicing in controlling
pituitary lineage expansion during development. In addition, we
performed quantitative RT-PCR analysis on the rb1 mRNA-
injected usp39 embryos and observed a 30% reduction of e2f4
expression compared to control uninjected usp39 mutants (Figure
S5A), indicating that e2f4 upregulation in usp39 mutant is
secondary to Rb1 loss of function. Futhermore, this was confirmed
by quantitative RT-PCR analysis on the e2f4 MO-injected usp39
embryos and observed that there was no change in rb1 expression
compared to control uninjected usp39 mutants (Figure S5B).
Discussion
In this study, we identified and functionally characterized the
zebrafish usp39 gene, important for human and yeast pre-mRNA
splicing [18,19]. We demonstrated that loss of usp39 results in
defects in rb1 mRNA splicing and downregulation of rb1
Table 2. Summary of cell cycle genes affected in usp39 mutant embryos from microarray hybridization and confirmed with
quantitative RT-PCR.
GB accession Unigene ID Location Gene Symbol Microarray Ratio RT-PCR Ratio
NM_213406 Dr.75152 chr11 cdk2 0.4 0.18
XM_689974 Dr.13764 chr14 pttg ND 1.3
NM_212564 Dr.24379 chr17 cdc2 0.53 0.36
NM_199430 Dr.80580 chr7 ccnb2 0.58 0.5
AF398516 Dr.75267 chr25 cdkn1b 0.57 0.53
AL912410 Dr.151578 chr22 cdkn1a ND 18
NM_152949 Dr.121874 chr14 ccna2 0.5 0.45
NM_131025 Dr.75056 chr7 ccnd1 0.82 0.65
NM_130995 Dr.29 chr7 ccne 0.52 0.54
NM_213432 Dr.77272 chr25 e2f4 2.8 3.09
NM_001077780 Dr.42121 chr21 rb1 0.49 0.34
XM_001922133 Dr.79466 chr25 rbl2 2.39 ND
ND indicates not determined.
doi:10.1371/journal.pgen.1001271.t002
Figure 6. Loss of usp39 leads to aberrant Rb1 mRNA splicing and increased pituitary e2f4 expression. A,B: Whole-mount double in situ
hybridization of pomc in red and e2f4 in purple at 48 hpf, lateral view. (A) Wild-type (wt) embryo. (B) Expression of e2f4 is higher and colocalizes with
pomc expression in usp39 mutant embryos. C–E and G–I: Whole-mount in situ hybridization of pomc at 48 hpf, ventral view, anterior to left. (C) wt. (D)
usp39 mutant. (E) e2f4-MO-injected usp39 mutant embryos showed partial pomc rescue similar to observed in wt embryonic pomc expression (C). F:
PCR product with primers designed for region between exon 3 and exon 4 of rb1 in wt and usp39 mutant embryos. wt embryos only contain a 250
base pair (bp) PCR band, indicating that the intron was correctly spliced out. However, in the usp39 mutants there is an additional 343 bp band that
contains the intron sequence. G–I: (G) wt. (H) usp39 mutant. (I) rb1 mRNA-injected usp39 mutants exhibit partial rescue of pomc expression similar to
wt embryos (G).
doi:10.1371/journal.pgen.1001271.g006
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well as rb1 downregulation in usp39 mutants may be explained by
nonsense-mediated mRNA decay due to a premature termination
codon. RB1 gene mutation leading to pre-mRNA splicing defects
have been shown in human cancers [33] and our study suggests a
novel mechanism resulting in rb1 splicing defects due to a usp39
mutation.
Control of pituitary progenitor cell proliferation in concert with
terminal differentiation during embryonic pituitary development is
poorly understood. In mouse pituitary primordia, attenuated
proliferation of cells destined to become hormone-expressing cell
types occurs days before lineage-specific hormones start to express
[34]. In contrast, zebrafish pituitary terminal differentiation is
initiated while progenitor cells are still organized in a placodal
fashion in the anterior neural ridge [2,16]. The usp39 mutants
demonstrated no early difference of adenohypophyseal primordia
compared with wt, until 48 hpf when terminally differentiated cells
had already migrated to a mature pituitary destination. Pituitary
lineage expansion became apparent at 48 hpf in usp39 mutants, as
indicated by expression of pituitary transcription factors and
lineage-specific hormone markers (Figure 3 and Figure 5).
Similarly, it was found that inactivation of Rb in the small
intestines of mice results in increased proliferation of differentiated
cells in the villus but not in the stem cells located in the base of the
crypts [35]. Therefore, our results suggest that loss of usp39 does
not affect pituitary specification, initiation and early differentia-
tion, but does induce lineage expansion at later development
stages when the cells are terminally differentiated.
Our results indicate that e2f4 overexpression has at least a
partial but direct affect on adenohypophyseal cell lineages in usp39
mutants, as e2f4 antisense MO knockdown partially reverted the
pituitary phenotype of usp39 mutants (Figure 6 and Figure S4).
The usp39 mutants demonstrated persistently upregulated e2f4
expression, although molecular mechanisms leading to e2f4
overexpression remain to be determined. Overexpression of e2f4
may exert oncogenic activity promoting cell-cycle progression as
previously indicated in pituitary, thyroid, lung neuroendocrine
hyperplasia [36], intestinal crypt cells, colorectal cancer cells [37]
as well as in prostate cancer [38]. We demonstrated an increase of
POMC-GFP-positive cells in the usp39 mutant embryos compare
to wt (Figure S2). Consequently, e2f4 upregulation in usp39
mutants may contribute to increased proliferation of terminally
differentiated pituitary cells leading to lineage expansion as seen in
our BrdU studies (Figure S2). On the other hand, E2F4 is a key
regulator associated with p130 to promote quiescent G0 and
terminal differentiation [13]. The cyclin kinase inhibitor, p21,
inhibits decay of the E2F4-p130 complex, promotes senescence
and restrains growth, contributing to the benign propensity of
pituitary adenomas [39,40]. Our microarray and quantitative RT-
PCR data showed increased cdkn1a (p21), e2f4 and rbl2 (p130),
which may indicate an enhanced quiescent G0 phase inducing
terminal differentiation and lineage expansion in usp39 mutants.
Although the focus of this study was the role of usp39 in pituitary
development, this gene is also expressed in neuronal tissues and
when mutated, embryos show microcephaly and smaller eyes,
therefore usp39 function may not be restricted to pituitary
development. We propose that usp39, through targeting a set of
key regulatory genes by modulating RNA splicing, should have a
broader role in regulating neuronal cell lineage development.
Although how usp39 controls target mRNA splicing remains to be
fully elucidated, the usp39 ortholog of the yeast protein Sad1p was
found to have two roles: it is involved in the assembly of U4
snRNP to U6 snRNP and is also required for splicing [18].
Furthermore, previous reports have shown that a zebrafish RNA
splicing factor, p110, is required for U4 and U6 snRNPs recycling,
and a mutation in p110 leads to thymic hypoplasia as well as eye
and exocrine pancreas defects [41]. In addition, microarray
analysis of p110 mutant shows a compensatory mechanism
inducing increased expression of other splicing factors, which
may reverse the recycling defects [41]. We observed a similar
result in our microarray analysis with upregulation of other U4/
U6.U5 tri-snRNP proteins, which suggests a compensatory
mechanism in usp39 mutants (Table S2 and Figure 6F). The
human tri-snRNP specific proteins include 65K, 110K and 27K
are encoded by USP39, SART1 and SNRNP27, respectively and
play a similar role in splicing [21]. Specifically, both sart1 and
snrnp27 were found to be upregulated in our microarray analysis
demonstrating a compensatory role due to the absence of usp39
(Table S2). Additionally, we discovered another neuronal gene,
otx2, which was also significantly downregulated due to a splicing
defect (Figure S6). However, otx2 mRNA overexpression in usp39
mutant embryos did not rescue the pituitary phenotype (data not
shown), validating that the Rb1/E2F4 pathway is more specific to
pituitary regulation. A systematic analysis of splicing variation of
all mRNA transcripts affected by usp39 deficiency will uncover
additional pathways that control neuronal and organ development
by RNA splicing mechanisms.
In summary, our findings indicate that usp39 plays an important
role in pituitary development by regulating rb1 and e2f4. Loss of
usp39 leads to pituitary cell lineage expansion through rb1
downregulation due to a splicing defect. In addition, e2f4
overexpression contributes to increased pituitary cell mass, likely
as a result of increased terminal differentiation or proliferation.
Our studies reveal a novel role of usp39-mediated mRNA splicing
of rb1 in pituitary cell growth control, which is critical for
maintaining embryonic pituitary homeostasis.
Materials and Methods
Mutagenesis and fish husbandry
Mutagenesis with ENU was performed as described [25].
Mutants including hp689 were identified from random sibling
crossing from F2 families giving rise to 25% altered pomc
expression at 48 hpf.
Genetic mapping
Linkage analysis was established by mating hp689 heterozygote
in an AB background to the WIK strain. Random sibling crossing
identified F1 carriers, and mutants were identified phenotypically
in F2 offspring at 48 hpf. We analyzed linkage between hp689 and
simple sequence-length polymorphism markers [42]. Linkage
analysis found the z34450 marker located 2.4 cM (4 recombina-
tions in 168 meiosis), G40879 marker located 0.3 cM (1
recombination in 288 meioses), ephb4a located 2.2 cM (5
recombinations in 114 meioses) and marker ndrg3 located
0.3cM (1 recombination in 310 meioses) in linkage group 5
(LG5) linked to the mutation.
Genotyping of usp39 mutants
Total RNA derived from 48 hpf mutant and wild-type embryos
was prepared by TRIZOL (Invitrogen) reagent extraction and
used to generate cDNA by SuperscriptII reverse transcriptase
(Invitrogen) with oligoDT primers (Roche Applied Science). The
region near marker ndrg3 contain 7 genes and sequencing the
usp39 full-length cDNA with primers CGCGTTCACAGT-
GCGTTC and TTTCTCATTGTGTGTTTTACTCAGTC
from mutant embryos revealed a point mutation that converted
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termination codon rather than a tyrosine residue.
Cloning of the zebrafish usp39 cDNA
The usp39 full-length cDNA fragment was generated from wild-
type embryos as described above and subcloned into pCRII-
TOPO.
Morpholino, mRNA synthesis, and microinjection
Antisense MO’swere injected into embryos as described [27].
The sequence of usp39 MO is 59-TTCACGCCTCTGATCA-
TATTTTAAG-39 and for e2f4 MO is 59-ACTCTCCCAT-
CGCTCCCAGGTCGTT-39 (Gene Tools, Inc). One- to two-cell
stage embryo was injected at 3.9 ng for the usp39 MO and 1.4 ng
of e2f4 MO. The usp39 overexpression construct was generated by
subcloning full-length usp39 cDNA from vector pCRII-usp39 into
the EcoRI site of vector pXT7. The pXT7-usp39 vector was
linearized with XbaI and mRNA was transcribed using
T7 mMessage mMachine kit (Ambion). The rb1 overexpression
construct was generated by subcloning full-length rb1 cDNA
(Accession Number: BC125966, Openbiosystems) to vector pCS2
+
in the StuI and XhoI sites. The rb1-pCS2
+ vector was then
linearized with XbaI and the mRNA transcribed using Sp6
mMessage mMachine kit (Ambion). mRNA injections were
performed at the one-cell stage at approximately 200 pg for
usp39 and 267 pg for rb1.
RNA in situ hybridization
Single and double whole-mount in situ hybridizations were
performed as described [43]. usp39 antisense probe was synthe-
sized from pCRII-usp39 with Sp6 RNA polymerase after
linearization with NotI. The following riboprobes were generated
from cDNAs as described: pomc [16], gh, prl, tshb, lim3, pit1 and
pitx3 [2], eya1 [44], crh [29], gnrh2 and gnrh3 [30], and ascl1a [31].
Full-length cDNA for cga (Accession Number: BC116611) and e2f4
(Accession Number: BC056832) were purchased from Open-
biosystems. e2f4 was subcloned to pCRII-TOPO vector and
linearized with SpeI whereas the cga-Express1 was linearized
with EcoRI and riboprobes were synthesized with T7 RNA
polymerase.
Antibody staining
Whole-mount antibody staining was performed using a rabbit
anti-tyrosine hydroxylase (TH) primary antibody at 1:200 dilution
(Chemicon) and detected with an Alexa (A594)-conjugated goat
anti-rabbit secondary antibody at 1:200 dilution (Molecular
Probes).
Microarray analysis
Total RNA from 48 hpf usp39 mutants and wild-type embryos
was prepared and microarray performed as described [45].
Quantitative RT-PCR
cDNA was generated as described above. RT-PCR was
performed using the iCycler iQ Real-Time PCR Detection
System (BioRad) and the iQ SYBR Green Supermix (Biorad).
Relative cDNA amounts were calculated using the iCycler
program (BioRad) and gene expression levels measured by the
2
2DDCT method [46], comparing usp39 mutant embryos to WT
controls, with b-actin used as the reference gene. This procedure
was repeated three times for each gene with three different
experimental cDNA pools. At least three replicates were used for
each cDNA pool. Gene expression was reported as relative
expression change in usp39 mutants over WT embryos 6 standard
error (for primer sequences see Table S1).
Retinoblastoma splicing primers
cDNA was generated as described above. We designed primers
that covered the exon and intron region of Exon 3 to Exon 4 of the
rb1 gene. The primers used were: CCGTATTCGAACAGA-
CAGCA and GGTAGAGGGCCAAAGTCACA.
Vibratome sections
After whole-mount in situ hybridization, embryos were washed
in PBS, manually deyolked, and mounted on their lateral side in
4% low melting agarose (Fisher Scientific) in PBS. Thin 100 mm
slices were cut using a vibratome (Vibratome 1000 Plus) and
sections were stored in PBS until imaging.
Image acquisition and processing
The in situ hybridization and the vibratome sections were
imaged with an Axiocam digital camera (Zeiss) mounted on an
Axioplan 2 compound microscope (Zeiss). OpenLab 4.0.2 software
(Improvision) was used to capture all images; Photoshop CS4
software (Adobe Systems) was used for further image processing.
Supporting Information
Figure S1 lim3 expression is not altered at 36 hpf. (A, B) Whole-
mount in situ hybridization with lim3 probe, ventral view with
anterior to left. (A) wild-type (wt). (B) Expression of lim3 in usp39
mutant embryos is not changed compared to wt embryos at 36
hpf.
Found at: doi:10.1371/journal.pgen.1001271.s001 (1.30 MB TIF)
Figure S2 Increase in pituitary cell number in usp39 mutants
compared to wt embryos. Immunocytochemistry using anti-GFP
antibody was performed on 5 mm frontal sections of wt and usp39
mutants with a POMC-GFP transgenic background at 48 hpf,
ventral view, anterior on top. The anti-GFP, rabbit IgG fraction,
Alexa Fluor 488 conjugated antibody are at 1:200 dilution
(Invitrogen). A drop of ProLong Gold antifade reagent with DAPI
(Invitrogen) was added to sections and coverslipped. (A, B) All
pituitary POMC-GFP-positive cells are included in two sequential
sections of the wild-type embryos. (C–E) Three sections are
required to include all pituitary POMC-GFP positive cells in usp39
mutant embryos. (F) Four wt and four usp39 mutants were
analyzed for POMC-GFP-positive cells. usp39 mutants had an
average of 25.5 POMC-GFP-positive cells compare to 12.5 in wt
embryos (mean 6 SEM; p,0.02, n=4). (G) To determine the
total number of pituitary cells, DAPI positive cells were counted in
the same sections of the four wt and four usp39 mutants. usp39
mutants had an average of 123.5 DAPI-positive cells in the
pituitary compare to 48.25 in wt embryos (mean 6 SEM; p,0.03,
n=4). (H–I) Embryos were placed in 10 mM solution of BrdU
(Sigma) in fish water at 10-somite stage and kept in dark until 48
hpf. The embryos were also injected with 10 nl of 10 mM Brdu at
24 hfp. BrdU labeling results in 48 hpf embryos by immunocy-
tochemistry using anti-GFP antibody and anti-BrdU was per-
formed in whole-mount embryos as described in [Liu et al]. The
anti-GFP, rabbit IgG fraction and Alexa Fluor 488 secondary
antibody are at 1:200 dilution (Invitrogen). The anti-BrdU, mouse
IgG fraction (Santa Cruz) and Alexa Fluor 594 secondary
antibody (Invitrogen) are at 1:100 and 1:200 dilution, respectively.
Imaging was performed on vibratome 100 mm sections of wt and
usp39 mutant embryos. (H) Proliferating cells in the pituitary were
not evident in wt embryos. (I) usp39 mutant embryos contain a
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by white arrowheads. [Liu NA, Ren M, Song J, Rios Y,
Wawrowsky K, et al. (2008) In vivo time-lapse imaging delineates
the zebrafish pituitary proopiomelanocortin lineage boundary
regulated by FGF3 signal. Dev Biol.]
Found at: doi:10.1371/journal.pgen.1001271.s002 (9.15 MB
TIF)
Figure S3 Quantitative RT-PCR analysis showing expression of
cell cycle regulators with loss of usp39. Relative gene expression
levels were calculated for usp39 mutant embryos compared to
control WT embryos (see Materials and Methods). Dashed line
represents a value of 1, which corresponds to no change in WT
expression. Significant change was determined by two standard
deviations (Mean 6 SEM).
Found at: doi:10.1371/journal.pgen.1001271.s003 (9.64 MB
TIF)
Figure S4 e2f4 morpholino injections rescued prl expression in
usp39 mutants. (A–C) Whole-mount in situ hybridization with prl
probe, ventral view with anterior to left. (A) wt. (B) usp39 mutant
embryo. (C) Expression of prl in e2f4-MO-injected usp39 embryos
was partially rescued.
Found at: doi:10.1371/journal.pgen.1001271.s004 (9.55 MB
TIF)
Figure S5 e2f4 mRNA expression is partially rescued by rb1
mRNA overexpression in usp39 mutant embryos while e2f4 MO
injections did not rescue rb1 mRNA levels. A 30% decrease of e2f4
expression was detected in the rb1 mRNA injected usp39 embryos
compared to control uninjected usp39 mutants by quantitative RT-
PCR (mean 6 SEM; n=60 embryos; p,0.03). (B) However, the
expression of rb1 mRNA levels by quantitative RT-PCR of usp39
mutants injected with e2f4 morpholino did not change (mean 6
SEM; n=67 embryos).
Found at: doi:10.1371/journal.pgen.1001271.s005 (9.49 MB TIF)
Figure S6 otx2 splicing defect in usp39 mutants. (A, B) Whole-
mount in situ hybridization of otx2 at 48 hpf, ventral view, anterior
to left. (A) wt. (B) Expression of otx2 is downregulated in usp39
mutants. (C) PCR product with primers designed for a region
between exon 3 and exon 4 of otx2 in wt and usp39 mutant
embryos. In addition to the 79 bp band in wt, the usp39 mutant
embryos contain an additional 289 bp band, which corresponds to
a mispliced mRNA fragment including the intron between exon 3
and 4. The primers used were: GGCCTTGAAAATCAACTTGC
and CTGCTGTTGGCGACACTTT.
Found at: doi:10.1371/journal.pgen.1001271.s006 (9.49 MB TIF)
Table S1 Quantitative RT-PCR primers.
Found at: doi:10.1371/journal.pgen.1001271.s007 (0.05 MB
DOC)
Table S2 Tri-snRNP factors affected in usp39 mutants.
Found at: doi:10.1371/journal.pgen.1001271.s008 (0.04 MB
DOC)
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